Clinical trials: Skin Infection
Skin Diseases, Infectious
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
To compare the safety and the efficacy of tigecycline to vancomycin with aztreonam in treating hospitalized patients with complicated skin and/or skin structure infections.
- Trial name
- NCT00228410
- Testing
- Tigecycline, vancomycin with aztreonam
- Volunteers
- 503 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Bacterial Skin and Skin Structure Infections
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in…
- Trial name
- NCT03137173
- Testing
- ceftobiprole medocaril, vancomycin+aztreonam
- Where
- 34 sites in United States, Bulgaria and 2 more
- Volunteers
- 679 people
- Sponsor
- Basilea Pharmaceutica
Onychomycosis
Efficacy and Safety of RV4104A Ointment in Onychomycosis
The purpose of the study is to evaluate the efficacy of RV4104A ointment versus bifonazole-urea ointment for the complete removal of the clinically infected nail plate area in patients with toenail onychomycosis.
- Trial name
- NCT00808366
- Testing
- Keratolytic/Antifungal
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Genital Herpes, HSV-2 Infection
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence.
- Trial name
- NCT03146403
- Testing
- GEN-003, Matrix-M2, 0.9% normal saline
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Genocea Biosciences, Inc.
Onychomycosis
Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of HTU-520 in subjects with clinically diagnosed onychomycosis of the great toenail.
- Trial name
- NCT01400594
- Testing
- HTU-520 Patch
- Where
- 37 sites in United States
- Volunteers
- 182 people
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
Onychomycosis
Diode Laser Treatment of Onychomycosis
The purpose of this study is to evaluate the V-Raser diode laser system with investigational Nail Fungus Handpiece in the treatment of onychomycosis.
- Trial name
- NCT01452490
- Testing
- Diode Laser Treatment
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ConBio, a Cynosure Company
Herpes Simplex
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.
- Trial name
- NCT01602562
- Testing
- VACV tablets (Adults or pediatrics) or granules (pediatrics)
- Where
- 11 sites in Japan
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Tinea Pedis
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.
- Trial name
- NAFT-600 (NCT01290341)
- Testing
- NAFT-600 (naftin 2 % gel)
- Where
- 23 sites in United States
- Volunteers
- 860 people
- Sponsor
- Merz North America, Inc.
Onychomycosis of Toenail
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution.
- Trial name
- NCT07065773
- Testing
- Trichostatin A
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanda Pharmaceuticals
Hidradenitis Suppurativa
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development.
- Trial name
- NCT06046729
- Testing
- Eltrekibart
- Where
- 74 sites in United States, Australia and 4 more
- Volunteers
- 352 people
- Sponsor
- Eli Lilly and Company
Onychomycosis
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the…
- Trial name
- NCT01208129
- Testing
- NAB001
- Where
- 25 sites in United States
- Volunteers
- 458 people
- Sponsor
- Promius Pharma, LLC
Tinea Cruris, Jock Itch
Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris
To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured.
- Trial name
- NCT01885156
- Testing
- Naftin 1% Cream
- Where
- 5 sites in Belize, Dominican Republic and 1 more
- Volunteers
- 65 people
- Sponsor
- Merz North America, Inc.
Skin Infections
Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection
The purpose of this study is to evaluate the potential effect and safety of two different doses of PZ-601 and to compare this with another antibiotic that is approved by the US Food and Drug Administration (also known as FDA) to…
- Trial name
- NCT00671580
- Testing
- PZ-601, Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 99 people
- Sponsor
- Protez Pharmaceuticals, Inc.
Skin Infections, Bacterial
United States Pharmacovigilence Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impetigo in persons nine or more…
- Trial name
- NCT01153880
- Testing
- Retapamulin, Co-prescription of retapamulin and topical mupirocin
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Skin Diseases, Infectious, Skin Diseases, Bacterial
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
- Conditions
- Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
- Trial name
- NCT00228982
- Testing
- Ceftobiprole medocaril, Vancomycin
- Volunteers
- 784 people
- Sponsor
- Basilea Pharmaceutica
Rheumatoid Arthritis
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.
- Trial name
- NCT00993668
- Testing
- Certolizumab pegol
- Where
- 41 sites in United States
- Volunteers
- 224 people
- Sponsor
- UCB Pharma
Herpes, Herpes Simplex
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by…
- Conditions
- Herpes, Herpes Simplex, Herpes Oral, Herpes Simplex 2
- Trial name
- NCT04664127
- Testing
- Kagocel+Valacyclovir, Valacyclovir
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Nearmedic Plus LLC
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Skin Condition, Skin Abnormalities
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
The goal of this observational study is to learn if an artificial intelligence (AI) tool helps primary care practitioners better identify skin conditions.
- Conditions
- Skin Condition, Skin Abnormalities, Malignancy, Melanoma (Skin Cancer)
- Trial name
- NCT07429123
- Testing
- Primary care practitioners aided by Legit.Health Plus
- Where
- Spain
- Volunteers
- 131 people
- Sponsor
- AI Labs Group S.L
Diabetic Foot Ulcer, Venous Leg Ulcer
DETEC® Esterase for Screening Wound Infection at Point of Care
This non-interventional, single-blinded, prospective, observational study assesses the planar distribution of leukocyte esterase in wounds by placing wound exudates soaked wound dressings in the DETEC® Esterase device during…
- Conditions
- Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
- Trial name
- NCT04614870
- Testing
- DETEC® Esterase
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Progenitec Inc.